← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV23행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
GM-CSF (GM-CSF)
David Avigan·Neuroblastoma
ORR 66%
Overview
Program
GM-CSF
Overview
Company
David Avigan
Overview
Modality
ANTIBODY
Overview
Target
Neuroblastoma
Overview
Indication
Multiple Myeloma; Relapse Multiple Myeloma
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Mechanism
targeting CD16 and the epidermal growth factor receptor
MoA
Biomarker
biomarkers to support personalized treatment strategies
PK/PD
Species
Mouse, Rat
PK/PD
Animal (cat.)
Mouse, Rat
PK/PD
Experiment
PD
Toxicology
Species
Mouse, Rat
Toxicology
Animal (cat.)
Mouse, Rat
Toxicology
Major finding
Neutrophil elastase-SERPINB1 axis in epithelial responses: Cell death, inflammation and SERPINB1 dynamics.. Chronic inflammatory lung diseases are associated with elevated levels of neutrophil elastase (NE), leading to epithelial damage and dysregulated cellular responses. However, the molecular mechanisms underlying NE-mediated disruption of epithelial anti-protease defenses, including the regula…
Clinical
Primary efficacy
ORR 66%
Clinical
ORR
66%
Clinical
PFS
48
Clinical
OS
65
Clinical
Result source
ClinicalTrials.gov NCT00098774
Clinical
Data Tier / Score
A · 63
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 8일 (6일 전)